Marcie Glicksman, PhD, joined Acelot as the Acting Chief Scientific Officer in 2024. She is an accomplished biotechnology executive with over 30 years of experience dedicated to developing innovative therapeutics, mainly for the nervous system and other complex therapeutics areas. Dr. Glicksman has held instrumental roles at multiple biotech companies and has an extensive track record of leadership. Her work has been essential in the development of eight drugs that have entered the clinic, two that became marketed products generating over $2 billion in sales for Cephalon (now Teva Pharmaceuticals) and Cubist (now Merck). She currently serves as Vice President Biology at EnClear Therapies, where she leads efforts to advance the company’s drug delivery programs, and is also a self-employed CSO consultant. Before her current position, she worked as a Consultant at 1910 Genetics, and held senior scientific roles at ORIG3N as Chief Scientific Officer, and at the Laboratory for Drug Discovery in Neurodegeneration, Harvard Medical School, Brigham Women’s Hospital as Director and Assistant Professor.

Dr. Glicksman has a PhD in Neuroscience from Washington University in St. Louis, and an AB in Human Biology from Brown University.